- Home
- RUBI vs RNAZ Comparison
RUBI vs RNAZ Comparison
Compare RUBI & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUBI | RNAZ |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RUBI | RNAZ |
|---|---|---|
| Price | $1.81 | $2.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 83.3K | 48.3K |
| Earning Date | 05-06-2020 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $1.83 |
| 52 Week High | $6.69 | $20.99 |
Technical Indicators
Market Signals| Indicator | RUBI | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 27.13 |
| Support Level | $1.63 | N/A |
| Resistance Level | $2.71 | $6.15 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 35.48 | 15.50 |
Price Performance
Historical ComparisonAbout RUBI Rubico Inc.
Rubico Inc is an international provider of crude oil transportation services. The Company is engaged in the ownership and operation of a fleet of tanker vessels designed for enhanced fuel efficiency and reduced greenhouse gas emissions, incorporating environmentally friendly technologies.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.